JUNSHI BIO (01877) has released an announcement revealing that in the first three quarters of 2026, the company recorded operating revenue of RMB 2.513 billion, representing a year-on-year increase of 39.18%.

The net loss attributable to shareholders of the listed company stood at RMB 149 million, narrowing by 75% compared with the same period last year.

Basic loss per share was RMB 0.15.